No Data
Lingkang Pharmaceutical: 2024 Annual Results Forecast
2024 Annual Results Forecast
Lionco Pharmaceutical Group (603669.SH): It is expected to have a net loss of approximately 0.12 billion yuan in 2024.
On January 16, GLONGHUI reported that Lionco Pharmaceutical Group (603669.SH) announced, based on preliminary calculations from the company's financial department, it is expected that the net income attributable to the parent company for the year 2024 will be around -120 million yuan, which represents a reduction in losses of approximately 20.79% compared to the same period last year (statutory disclosed data). It is expected that the net income attributable to the parent company, excluding non-recurring gains and losses, will be around -165 million yuan, reflecting a reduction in losses of about 9.26% compared to the same period last year (statutory disclosed data). It is expected that the revenue for the year 2024 will be around 380 million yuan, compared to the same period last year (law.
Private Companies Among Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 11% Last Week
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. participated in the tenth batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the public announcement of the proposed selection results of national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's product, injectable ceftazidime sodium, is proposed to be selected for this centralized procurement. The sales revenue of injectable ceftazidime sodium from Lionco Pharmaceutical's wholly-owned subsidiary in 2023 amounted to 0 million yuan, accounting for 0% of the company's revenue for the year 2023; sales for the first three quarters of 2024.
Revenues Not Telling The Story For Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) After Shares Rise 29%
Some Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Shareholders Look For Exit As Shares Take 31% Pounding